A Randomized, Multicenter, Double-blind, Placebo-controlled comparison of chemotherapy
08/29/2012 - 02/28/2021 (PI)Genentech, Inc.
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer
03/13/2014 - 03/12/2019 (PI)Celldex Therapeutics, Inc.
A Randomized, 3 Arm, Multi-Center, Phase III Study to Evaluate the Efficacy and the Safety or T-DM1 Combined with Pertuzumab or T-DM1 Combined with Pertuzumab-Placebo (Blinded for Pertuzumab), versus
11/23/2010 - 05/11/2016 (PI)Genentech, Inc.
A RANDOMIZED, MULTICENTER, PHASE III OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMABMCC-DM1 VS. CAPECITABINE + LAPATINIB IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC
02/23/2009 - 11/21/2012 (PI)Genentech, Inc.
A Phase III Randomized Double Blind Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Vs Placebo + Trastuzumab+ Docetaxel in Previously
02/23/2009 - 03/31/2012 (PI)Genentech, Inc.
Phase II Multi-Center, Randomized, Blinded Placebo-Controlled Trial of Carboplatin & Gemcitabine plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallo
01/14/2008 - 01/13/2012 (PI)Genentech, Inc.
A Phase III, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG or Placebo in Women With Recurrent Partiality Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or
12/02/2010 - 11/30/2011 (PI)Amgen, Inc.
CA023: A Randomized Phase II Trial of Weekly vs Every 2 Wk vs Every 3 Wk Administration of ABI-007 in Combination of Bevacizumab in Women with Metastatic Breast
01/25/2007 - 09/23/2011 (PI)Abraxis Bioscience, Inc.
Phase 3, Multicenter, Open Label Study to Evaluate the Safety and Efficacy of Alfimeprase in Subjects with Occluded Central Venous Access Devices
09/27/2006 - 09/26/2008 (PI)Nuvelo, Inc.
A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes and Refractory to the Most Recent Chemother
08/30/2007 - 08/29/2008 (PI)Eisai Medical Research Institute, Inc.
Showing 10 of 21 results.
Show All Results